• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Supernus Announces Second Quarter 2024 Financial Results

    8/6/24 4:06:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SUPN alert in real time by email
    • Net sales of Qelbree® increased 92% in the second quarter of 2024, compared to the same period in 2023.



      • $59.4 million and $104.5 million of net sales in the second quarter and first six months of 2024, respectively.
    • Net sales of GOCOVRI® increased 10% in the second quarter of 2024, compared to the same period in 2023.



      • $31.7 million and $58.3 million of net sales in the second quarter and first six months of 2024, respectively.
    • Total revenues were $168.3 million in the second quarter of 2024, an increase of 24% compared to the same period in 2023.



      • Total revenues excluding Trokendi XR® and Oxtellar XR® net product sales (non-GAAP)(1) increased 32% in the second quarter of 2024, compared to the same period in 2023.

    • Operating income of $22.6 million and $19.4 million in the second quarter and first six months of 2024.
    • Adjusted operating earnings (non-GAAP)(1) was $45.5 million and $67.7 million in the second quarter and first six months of 2024, respectively, compared to $10.0 million and $40.5 million in the same periods in 2023.
    • Raising full year 2024 guidance for total revenues and operating earnings (GAAP and Non-GAAP).

    ROCKVILLE, Md., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the second quarter of 2024 and associated Company developments.

    Business Highlights

    • Total IQVIA prescriptions for Qelbree were 184,342 in the second quarter 2024, an increase of 26% compared to the same period in the prior year.
    • In August 2024, the Company resubmitted its New Drug Application (NDA) for its apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations ("off" episodes) in Parkinson's disease.

    "In the second quarter of 2024, we delivered strong net sales growth from our key growth drivers, Qelbree and GOCOVRI, as well as strong growth in adjusted operating earnings. We also advanced our product pipeline, announcing interim results from our open-label Phase 2a clinical study of SPN-817 for treatment-resistant seizures, and continued to progress SPN-820 through two Phase 2 studies in patients with depression," said Jack Khattar, President and CEO of Supernus. "Continued growth from Qelbree and GOCOVRI, together with pipeline progress, gives us confidence in delivering on our increased guidance and our operational objectives for 2024."

    Product Pipeline Update

    SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression

    • Nearly three-quarters of the planned patients have been enrolled in the ongoing Phase IIb multi-center randomized double-blind placebo-controlled parallel design study of SPN-820 in adults with treatment-resistant depression. The study will examine the efficacy and safety of SPN-820 over a course of five weeks of treatment in approximately 268 patients in up to 50 clinical sites. The primary outcome measure is the change from baseline to end of treatment period on the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score. Topline data from the Phase IIb trial are expected in the first half of 2025.
    • Enrollment is ongoing in the Phase II open-label study in patients with major depressive disorder (MDD). The primary objective of the study is to assess efficacy in MDD, as well as onset of efficacy. Topline results from the study are expected by the end of 2024.

    SPN-817 – Novel first-in-class highly selective AChE inhibitor for epilepsy

    • In May 2024, the Company announced data from the planned interim analysis of its exploratory open-label Phase IIa clinical study of SPN-817 for treatment-resistant seizures. The interim analysis was based on 41 enrolled subjects, of which 19 completed the maintenance period. The Company continues to expect topline results for the full study in the second half of 2024.
    • A Phase IIb randomized, double-blind, placebo-controlled study in patients with treatment resistant focal seizures is expected to start by the end of 2024.

    SPN-443 – Novel stimulant for ADHD/CNS

    • The Company plans to initiate a Phase I single dose study in healthy adults in 2024 following submission of an Investigational New Drug application. The primary objective of the study is to assess safety and tolerability.

    Financial Highlights

    This section includes information on non-GAAP financial measures. See "Non-GAAP Financial Information" section for information on non-GAAP financial measures. In addition, a reconciliation of applicable GAAP to non-GAAP financial information is included at the end of this press release.

    Revenues

    The following table provides information regarding total revenues (dollars in millions):

     Three Months Ended June 30,  Six Months Ended June 30, 
      2024   2023  Change %  2024   2023  Change %
    Net product sales           
    Qelbree$59.4  $31.0   92% $104.5  $56.8   84%
    GOCOVRI 31.7   28.8   10%  58.3   54.8   6%
    Oxtellar XR 29.5   23.8   24%  56.5   52.7   7%
    APOKYN 17.3   17.6   (2)%  33.9   34.8   (2)%
    Trokendi XR 17.1   19.3   (12)%  33.1   54.1   (39)%
    Other(2) 7.5   7.8   (4)%  14.7   15.7   (6)%
    Total net product sales 162.5   128.3   27%  301.0   268.9   12%
    Royalty, licensing and other revenues(3) 5.8   7.2   (20)%  11.0   20.4   (46)%
    Total revenues$168.3  $135.5   24% $312.0  $289.3   8%
                
    Total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP)(1)$121.7  $92.4   32% $222.4  $182.5   22%
                            
    • Total revenues were $168.3 million and $312.0 million for the three and six months ended June 30, 2024, compared to $135.5 million and $289.3 million in the same period in 2023.
      • Total net product sales were $162.5 million and $301.0 million for the three and six months ended June 30, 2024, compared to $128.3 million and $268.9 million in the same period in 2023, respectively. The increase in both periods was primarily due to the increase in net sales of Qelbree, GOCOVRI and Oxtellar XR, partially offset by the decline in net product sales of Trokendi XR due to generic erosion.
      • Total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP) increased 32% and 22% for the three and six months ended June 30, 2024, compared to the same period in 2023.

    Other Financial Highlights

    • Operating earnings was $22.6 million and $19.4 million for the three and six months ended June 30, 2024, compared to operating loss of $(17.6) million and $(12.4) million for the same periods in 2023, respectively. The positive increase in both periods was primarily due to an increase in total net product sales.
    • Adjusted operating earnings (non-GAAP) were $45.5 million and $67.7 million for the three and six months ended June 30, 2024, compared to $10.0 million and $40.5 million for the same periods in 2023, respectively.
    • Net earnings (loss) and diluted earnings (loss) per share were $19.9 million and $0.36 for the three months and $20.0 million and $0.36 for the six months ended June 30, 2024, respectively, compared to $(0.8) million and $(0.02) for the three months and $16.1 million and $0.29 for the six months ended June 30, 2023, respectively.
    • At June 30, 2024, cash, cash equivalents, and current and long-term marketable securities were approximately $347.2 million compared to $271.5 million as of December 31, 2023. This increase was primarily due to cash generated from operations.

    Full Year 2024 Financial Guidance

    For the full year 2024, the Company is increasing prior financial guidance for total revenues, GAAP operating earnings (loss) and non-GAAP operating earnings, and maintaining guidance for combined R&D and SG&A expenses as set forth below (dollars in millions).

     Current Guidance

    (as of August 6, 2024)
     Previous Guidance

    (as of May 8, 2024)
    Total revenues (includes approximately $135 - $145 million of Trokendi XR and Oxtellar XR)(4)(5)$600 - $625 $580 - $620
    Combined R&D and SG&A expenses$430 - $460 $430 - $460
    Operating earnings (loss)$0 - $20 $(30) - $(0)
    Adjusted operating earnings (non-GAAP)(1)$100 - $125 $80 - $110
        

    Non-GAAP Financial Information

    This press release contains financial measures that present financial information which do not comply with United States generally accepted accounting principles (GAAP). The non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, or superior to measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings on a historical and projected basis adjusts for non-cash share-based compensation expense, depreciation and amortization, intangible asset impairment charges and changes to fair value of contingent consideration, and for factors that are unusual, non-recurring or unpredictable, and excludes those costs, expenses, and other specified items presented in the reconciliation tables in this press release. In addition to non-GAAP adjusted operating earnings, we also present total revenues excluding net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP), which is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP). Beginning in the year a product loses exclusivity due to generic entrants we generally do not expect net product sales of such products to constitute a significant part of our revenue in the future. We believe that the use of non-GAAP financial measures provides useful supplemental information to management, investors, analysts and others regarding the Company's revenue and results of operations and assist management, investors, analysts, and others in understanding and evaluating our revenue growth and the performance of the business.

    There are limitations associated with the use of non-GAAP financial measures and therefore comparability may be limited. These limitations include: non-GAAP financial measures that may not be entirely comparable to similarly titled measures used by other companies; these may not reflect all items of income and expense, as applicable, that affect our operations; there may be potential differences among calculation methodologies; these may differ from the non-GAAP information used by other companies, including peer companies. We mitigate these limitations by reconciling the non-GAAP financial measure to the most comparable GAAP financial measure. Investors are encouraged to review the reconciliation. The Company's 2024 financial guidance is also being provided on both a GAAP and a non-GAAP basis.

    End Notes

    (1) See the section titled "Non-GAAP Financial Information" for information about this non-GAAP financial measure. A reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure is included at the end of this press release.

    (2) Includes net product sales of MYOBLOC®, XADAGO® and Osmolex ER®.

    (3) Royalty, licensing, and other revenues include royalties on generic Trokendi XR, other licensed products and intellectual property.

    (4) Includes net product sales and royalty, licensing, and other revenue.

    (5) Reflects continued generic erosion of Trokendi XR and generic erosion of Oxtellar XR beginning in September 2024.

    Conference Call Details

    Supernus will host a conference call and webcast today, August 6, 2024, at 4:30 p.m. Eastern Time to discuss these results. A live webcast will be available in the Events & Presentations section of the Company's Investor Relations website www.supernus.com/Investors.

    Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.

    Following the live call, a replay will be available on the Company's Investor Relations website www.supernus.com/Investors. The webcast will be available on the Company's website for 60 days following the live call.

    About Supernus Pharmaceuticals, Inc.

    Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

    Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson's disease (PD), cervical dystonia, chronic sialorrhea, and dyskinesia in PD patients receiving levodopa-based therapy. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders.

    For more information, please visit www.supernus.com.

    Forward-Looking Statements

    This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company's ability to increase its net revenue from its products and the products of its subsidiaries; the Company's ability to commercialize its products and the products of its subsidiaries; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.



    Supernus Pharmaceuticals, Inc.

    Condensed Consolidated Balance Sheets

    (in thousands, except share data)
        
     June 30, December 31,
      2024   2023 
     (unaudited)  
    Assets   
    Current assets   
    Cash and cash equivalents$52,089  $75,054 
    Marketable securities 295,098   179,820 
    Accounts receivable, net 152,494   144,155 
    Inventories, net 68,155   77,408 
    Prepaid expenses and other current assets 23,166   16,676 
    Total current assets 591,002   493,113 
    Long-term marketable securities —   16,617 
    Property and equipment, net 12,274   13,530 
    Intangible assets, net 559,644   599,889 
    Goodwill 117,019   117,019 
    Other assets 35,890   37,505 
    Total assets$1,315,829  $1,277,673 
        
    Liabilities and stockholders' equity   
    Current liabilities   
    Accounts payable and accrued liabilities$82,611  $79,569 
    Accrued product returns and rebates 175,119   154,274 
    Contingent consideration, current portion 47,303   52,070 
    Other current liabilities 3,623   4,283 
    Total current liabilities 308,656   290,196 
    Contingent consideration, long-term 697   1,380 
    Operating lease liabilities, long-term 30,294   33,196 
    Deferred income tax liabilities, net 11,440   24,963 
    Other liabilities 7,288   6,422 
    Total liabilities 358,375   356,157 
        
    Stockholders' equity   
    Common stock, $0.001 par value; 130,000,000 shares authorized; 55,046,049 and 54,723,356 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 55   55 
    Additional paid-in capital 455,170   439,493 
    Accumulated other comprehensive loss, net of tax (372)  (593)
    Retained earnings 502,601   482,561 
    Total stockholders' equity 957,454   921,516 
        
    Total liabilities and stockholders' equity$1,315,829  $1,277,673 





    Supernus Pharmaceuticals, Inc.

    Condensed Consolidated Statements of Earnings (Loss)

    (in thousands, except share and per share data)
     
     Three Months Ended

    June 30,
     Six Months Ended

    June 30,
      2024   2023   2024   2023 
     (unaudited) (unaudited)
    Revenues       
    Net product sales$162,538  $128,336  $300,999  $268,911 
    Royalty, licensing and other revenues 5,787   7,227   10,970   20,416 
    Total revenues 168,325   135,563   311,969   289,327 
            
    Costs and expenses       
    Cost of goods sold(a) 17,916   21,091   34,225   44,551 
    Research and development 26,183   24,379   51,113   45,591 
    Selling, general and administrative 85,904   86,782   172,420   172,379 
    Amortization of intangible assets 20,108   20,108   40,245   40,074 
    Contingent consideration expense (gain) (4,355)  790   (5,450)  (857)
    Total costs and expenses 145,756   153,150   292,553   301,738 
            
    Operating earnings (loss) 22,569   (17,587)  19,416   (12,411)
            
    Other income (expense)       
    Interest and other income, net 3,733   1,370   7,129   6,716 
    Interest expense —   (910)  —   (2,415)
    Total other income (expense) 3,733   460   7,129   4,301 
            
    Earnings (loss) before income taxes 26,302   (17,127)  26,545   (8,110)
            
    Income tax expense (benefit) 6,386   (16,296)  6,505   (24,227)
    Net earnings (loss)$19,916  $(831) $20,040  $16,117 
            
    Earnings (loss) per share       
    Basic$0.36  $(0.02) $0.37  $0.30 
    Diluted$0.36  $(0.02) $0.36  $0.29 
            
    Weighted average shares outstanding       
    Basic 54,978,781   54,502,993   54,890,265   54,442,463 
    Diluted 55,724,283   54,502,993   55,675,474   59,035,154 
                    
    (a) Excludes amortization of intangible assets.





    Supernus Pharmaceuticals, Inc.

    Reconciliations of GAAP to Non-GAAP Financial Information

    (Unaudited)
     

    Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR and Oxtellar XR net product sales

    An itemized reconciliation between total revenues on a GAAP basis and Total revenues excluding Trokendi XR and Oxtellar XR net product sales, a non-GAAP measure, is as follows (dollars in millions):

     Three Months Ended June 30,   Six Months Ended June 30,  
      2024   2023  Change %  2024   2023  Change %
    Total revenues (GAAP)(1)$168.3  $135.5   24% $312.0  $289.3   8%
    Adjustments:           
    Trokendi XR net product sales (17.1)  (19.3)  (12)%  (33.1)  (54.1)  (39)%
    Oxtellar XR net product sales (29.5)  (23.8)  24%  (56.5)  (52.7)  7%
    Total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP)(1)$121.7  $92.4   32% $222.4  $182.5   22%
                            
    (1) Includes net product sales and royalty, licensing, and other revenues.



    Reconciliation of GAAP Operating earnings (loss) to Non-GAAP Adjusted Operating earnings

    An itemized reconciliation between operating earnings (loss) on a GAAP basis and adjusted operating earnings on a non-GAAP basis is as follows (dollars in millions):

     Three Months Ended

    June 30,
     Six Months Ended

    June 30,
      2024   2023   2024   2023 
    Operating earnings (loss) - As Reported (GAAP)$22.6  $(17.6) $19.4  $(12.4)
    Adjustments:       
    Amortization of intangible assets 20.1   20.1   40.2   40.1 
    Share-based compensation 6.6   6.1   12.4   12.4 
    Contingent consideration expense (gain) (4.4)  0.8   (5.5)  (0.9)
    Depreciation 0.6   0.6   1.2   1.3 
    Operating earnings - As Adjusted (non-GAAP)$45.5  $10.0  $67.7  $40.5 
     

    Non-GAAP adjusted operating earnings adjusts for non-cash items including amortization of intangible assets, share-based compensation expense, change in fair value of contingent consideration, and depreciation.

    Reconciliation of Full Year 2024 Financial Guidance - GAAP Operating earnings (loss) to Non-GAAP Adjusted Operating earnings

    An itemized reconciliation between projected operating earnings (loss) on a GAAP basis for the full year 2024 and projected adjusted operating earnings on a non-GAAP basis for the full year 2024 is as follows (dollars in millions):

     Current Guidance

    (as of August 6, 2024)
     Previous Guidance

    (as of May 8, 2024)
    Operating earnings (loss) - GAAP$0 - $20 $(30) - $0
    Adjustments:   
    Amortization of intangible assets$78 - $80 $80 - $81
    Share-based compensation$27 - $29 $27 - $29
    Contingent consideration expense (gain)$(7) - $(7) $1 - $2
    Depreciation$2 - $3 $2 - $3
    Operating earnings - As Adjusted (non-GAAP)$100 - $125 $80 - $110



    CONTACTS:

    Jack A. Khattar, President and CEO

    Timothy C. Dec, Senior Vice President and CFO

    Supernus Pharmaceuticals, Inc.

    (301) 838-2591

    or

    INVESTOR CONTACT:

    Peter Vozzo

    ICR Westwicke

    (443) 213-0505

    [email protected]



    Primary Logo

    Get the next $SUPN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SUPN

    DatePrice TargetRatingAnalyst
    2/19/2025$57.00 → $36.00Overweight → Neutral
    Cantor Fitzgerald
    1/6/2025$57.00Overweight
    Cantor Fitzgerald
    9/11/2024$41.00 → $36.00Overweight → Neutral
    Piper Sandler
    1/3/2023$44.00 → $45.00Buy
    Jefferies
    12/1/2021$40.00 → $44.00Buy
    Jefferies
    More analyst ratings

    $SUPN
    SEC Filings

    See more
    • Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

      6/17/25 4:40:35 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

      6/16/25 8:34:38 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

      5/28/25 4:09:14 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Supernus Pharma downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously

      2/19/25 7:05:55 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Supernus Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Supernus Pharma with a rating of Overweight and set a new price target of $57.00

      1/6/25 8:47:11 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $41.00 previously

      9/11/24 7:45:40 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO Khattar Jack A. acquired 16,850 shares and disposed of 16,850 shares, increasing direct ownership by 2% to 1,008,683 units (SEC Form 4)

      4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

      4/3/25 4:27:28 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Khattar Jack A. converted options into 35,000 shares and covered exercise/tax liability with 16,805 shares, increasing direct ownership by 2% to 991,833 units (SEC Form 4)

      4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

      3/11/25 4:17:35 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Senior Vice-President & CFO Dec Timothy C converted options into 3,800 shares and covered exercise/tax liability with 2,017 shares, increasing direct ownership by 16% to 12,681 units (SEC Form 4)

      4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

      3/11/25 4:15:41 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Financials

    Live finance-specific insights

    See more
    • Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

      Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe

      6/16/25 7:00:06 AM ET
      $SAGE
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Announces First Quarter 2025 Financial Results

      First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 26% compared to the first quarter of 2024.First quarter 2025 operating loss of $(10.3) million, compared to operating loss of $(3.2) million in 2024. First quarter adjusted operating earnings (non-GAAP)(1) increased 16% to $25.9 million.ONAPGO™ (apomorphine hydrochloride

      5/6/25 4:08:06 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

      ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2025 financial and business results on Tuesday, May 6, 2025 at 4:30 p.m. ET. Following management's prepared remarks and discussion of business results, the call will

      4/23/25 5:14:00 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Leadership Updates

    Live Leadership Updates

    See more
    • Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

      Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa

      10/16/23 5:34:21 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

      Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe

      6/16/25 7:00:06 AM ET
      $SAGE
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

      ROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer. The series, which launches its first episode on the All About ADHD YouTube channel in May for Mental Health Awareness Month, offers an intimate look at how ADHD impacts relationships and how Qelbree (viloxazine extended-release capsules), a non-stimulant ADHD treatment for people 6 years and older, has played a role in Jay's ADHD treatment journey.  The four-part video series delves into Jay's experience with ADHD through the lens of his relationship with Rosie, offering unique pe

      5/29/25 8:30:51 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Announces Paragraph IV ANDA Filings for Qelbree®

      ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company received Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules, eq. 100, 150, and 200 mg base. Supernus is currently reviewing the details of these Notice Letters and intends to vigorously enforce its intellectual property rights relating to Qelbree. The U.S. Food and Drug Administration's Orange Book

      5/28/25 4:05:32 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

      SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

      11/14/24 5:14:42 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

      SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

      11/1/24 4:35:56 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Supernus Pharmaceuticals Inc.

      SC 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

      10/31/24 11:55:00 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care